Annual Report 2017 Active Biotech AB (publ)
April 23 2018 - 5:30AM
PRESS RELEASE
Active Biotech's Annual Report 2017 is now
available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English
version will be available within short.
Lund, April 23, 2018
Active Biotech AB (publ)
Helén Tuvesson
CEO
For further information, please
contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties is in development for neurodegenerative diseases in
partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an
immunotherapy, in development for cancer indications in partnership
with NeoTX Therapeutics Ltd. Furthermore, commercial activities are
conducted for the tasquinimod, paquinimod and SILC projects. Please
visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information
that Active Biotech AB is obliged to make public pursuant to the
Securities Markets Act. The information was submitted for
publication at 11.30 am CET on April 23, 2018..
Annual Report 2017 Active Biotech
AB (publ)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024
